EPTINEZUMAB FOR THE PREVENTIVE TREATMENT OF MIGRAINE: REAL-WORLD DATA FROM THE NEUROLOGY DEPARTMENT OF THE ATHENS NAVAL HOSPITAL IN GREECE

Abstract

Background: Eptinezumab is the first anti-CGRP monoclonal antibody administered intravenously for migraine prevention. Objective: To evaluate the effectiveness and safety of eptinezumab in patients with episodic and chronic migraine during the first trimester of treatment in a real-world clinical setting.

Methods: Seven patients received eptinezumab 100 mg intravenously. Baseline and 3-month assessments
included monthly migraine days (MMDs), pain intensity, days of acute medication use and quality of life indices (HIT-6, MIDAS).

Results: The cohort comprised six women and one man, mean age 40 years,
mean migraine onset at 24 years. Five had episodic migraine without aura, one episodic migraine with
aura, and one chronic migraine. All had failed at least two previous preventive treatments. At baseline,
patients reported a mean of 10 MMDs, pain intensity 9/10, 15 days of acute medication use/month,
mean MIDAS score 36 and HIT-6 score 70 (severe disability). After 3 months of treatment, MMDs
decreased by 60% (mean 4 days), pain intensity to 4/10, and acute medication days by 75% (mean 4 days). MIDAS improved to 8 and HIT-6 to 44 (mild/none disability). No adverse events were observed.

Conclusions: Eptinezumab was effective and well tolerated, substantially reducing migraine frequency,
pain intensity, and acute medication use, while improving quality of life. Its intravenous administration and
bioavailability may provide clinical advantages.